Glycopyrrolate Patent Expiration
Glycopyrrolate is Used for managing chronic obstructive pulmonary disease (COPD) through maintenance treatment of airflow obstruction. It was first introduced by Casper Pharma Llc
Glycopyrrolate Patents
Given below is the list of patents protecting Glycopyrrolate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lonhala Magnair Kit | US10744277 | Aerosol delivery device and method of operating the aerosol delivery device | Dec 07, 2036 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10688518 | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator | Nov 12, 2036 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10376661 | Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element | Sep 14, 2035 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9604018 | Aerosol therapy device | May 16, 2033 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9168556 | Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer | Sep 01, 2032 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9789270 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | Oct 30, 2030 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US10940110 | Method and system for the treatment of chronic COPD with nebulized anticholinergic administrations | Feb 26, 2029 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US9265900 | Disposable ampoule for an aerosol generating device | Dec 07, 2028 | Sumitomo Pharma Am |
| Seebri | US8182838 | Dry powder composition comprising co-jet milled particles for pulmonary inhalation | Oct 20, 2028 | Novartis |
| Seebri | US8479730 | Inhaler device | Oct 11, 2028 | Novartis |
| Lonhala Magnair Kit | US11278683 | Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized | Aug 16, 2026 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US7931212 | Fluid droplet production apparatus and method | Nov 25, 2025 | Sumitomo Pharma Am |
| Lonhala Magnair Kit | US7458372 | Inhalation therapy device | Nov 18, 2024 | Sumitomo Pharma Am |
| Robinul | US7091236 | Method for increasing the bioavailability of glycopyrrolate |
Apr 24, 2024
(Expired) | Casper Pharma Llc |
| Robinul Forte | US7091236 | Method for increasing the bioavailability of glycopyrrolate |
Apr 24, 2024
(Expired) | Casper Pharma Llc |
| Lonhala Magnair Kit | US8511581 | Fluid droplet production apparatus and method |
Nov 08, 2023
(Expired) | Sumitomo Pharma Am |
| Cuvposa | US7638552 | Method for increasing the bioavailability of glycopyrrolate |
Aug 20, 2023
(Expired) | Merz Pharms |
| Cuvposa | US7816396 | Method for increasing the bioavailability of glycopyrrolate |
Aug 20, 2023
(Expired) | Merz Pharms |
| Lonhala Magnair Kit | US7316067 | Forming a perforate membrane by laser drilling and a subsequent electro-polishing step |
Sep 06, 2022
(Expired) | Sumitomo Pharma Am |
| Seebri | US7736670 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US8048451 | Pharmaceutical compositions for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US8303991 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US8435567 | Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US8580306 | Particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US8956661 | Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US9931304 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US9962338 | Method of making particles for use in a pharmaceutical composition |
Jun 27, 2021
(Expired) | Novartis |
| Seebri | US7229607 | Treatment of respiratory disease |
Apr 09, 2021
(Expired) | Novartis |
| Seebri | US8029768 | Treatment of respiratory diseases |
Apr 09, 2021
(Expired) | Novartis |
| Lonhala Magnair Kit | US6962151 | Inhalation nebulizer |
Oct 27, 2020
(Expired) | Sumitomo Pharma Am |
| Seebri | US6528678 | Phosgene-free process for preparing carbamates |
Apr 24, 2018
(Expired) | Novartis |
| Seebri | US6582678 | Carrier particles for use in dry powder inhalers |
Apr 24, 2018
(Expired) | Novartis |
| Seebri | US6521260 | Carrier particles for use in dry powder inhalers |
Jan 31, 2016
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Glycopyrrolate's patents.
Latest Legal Activities on Glycopyrrolate's Patents
Given below is the list recent legal activities going on the following patents of Glycopyrrolate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed Critical | 24 Jun, 2024 | US8303991(Litigated) |
| Expire Patent Critical | 04 Dec, 2023 | US8048451 |
| Maintenance Fee Reminder Mailed Critical | 19 Jun, 2023 | US8048451 |
| Expire Patent Critical | 27 Mar, 2023 | US8956661 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Mar, 2023 | US8029768 |
| Maintenance Fee Reminder Mailed Critical | 10 Oct, 2022 | US8956661 |
| Expire Patent Critical | 18 Jul, 2022 | US7736670 |
| Expire Patent Critical | 13 Jun, 2022 | US9962338 |
| Expire Patent Critical | 10 May, 2022 | US9931304 |
| Maintenance Fee Reminder Mailed Critical | 31 Jan, 2022 | US7736670 |
Glycopyrrolate's Family Patents
Explore Our Curated Drug Screens
Glycopyrrolate Generic API Manufacturers
Several generic applications have been filed for Glycopyrrolate. The first generic version for Glycopyrrolate was by Watson Laboratories Inc and was approved on Approved Prior to Jan 1, 1982. And the latest generic version is by Saptalis Pharmaceuticals Llc and was approved on Oct 7, 2024.
Given below is the list of companies who have filed for Glycopyrrolate generic, along with the locations of their manufacturing plants worldwide.
1. ABRAXIS PHARM
Abraxis Pharmaceutical Products has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Abraxis Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Jun 12, 1984 |
2. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Jul 8, 2020 |
3. ADAPTIS
Adaptis Pharma Private Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Adaptis.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Feb 3, 2014 |
| 1MG | tablet | Prescription | ORAL | AA | Feb 3, 2014 |
4. ALEMBIC
Alembic Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Alembic.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Nov 30, 2018 |
| 1MG | tablet | Prescription | ORAL | AA | Nov 30, 2018 |
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 26, 2022 |
Manufacturing Plant Locations New
Alembic's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Alembic as present at those locations.
| Country | City | Firm Name | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||
5. AM REGENT
American Regent Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Am Regent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Jul 23, 1986 |
6. AMNEAL
Amneal Eu Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 21, 2022 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
7. ANNORA PHARMA
Annora Pharma Private Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Annora Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/5ML | solution | Prescription | ORAL | AA | Jul 5, 2022 |
Manufacturing Plant Locations New
Annora Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Annora Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
8. APOTEX
Apotex Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 29, 2019 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
9. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Prescription | ORAL | AA | Apr 15, 2013 |
| 2MG | tablet | Prescription | ORAL | AA | Oct 30, 2018 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
10. CAPLIN
Caplin Steriles Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Caplin.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Mar 20, 2019 |
Manufacturing Plant Locations New
Caplin's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Caplin as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
| India |
| |||
11. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 3 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Discontinued | ORAL | N/A | Dec 22, 2004 |
| 1MG | tablet | Discontinued | ORAL | N/A | Dec 22, 2004 |
| 1MG/5ML | solution | Prescription | ORAL | AA | Aug 28, 2024 |
12. DR REDDYS LABS LTD
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Mar 21, 2008 |
| 1MG | tablet | Prescription | ORAL | AA | Mar 21, 2008 |
13. ENDO OPERATIONS
Endo Operations Ltd has filed for 3 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG
(reference standard) | tablet | Prescription | ORAL | AA | Aug 31, 2006 |
| 1MG
(reference standard) | tablet | Prescription | ORAL | AA | Aug 31, 2006 |
| 1MG/5ML | solution | Prescription | ORAL | AA | Aug 9, 2021 |
14. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Nov 28, 2018 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
15. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 31, 2018 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
16. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Sep 30, 2019 |
17. GRANULES
Granules Pharmaceuticals Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Granules.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/5ML | solution | Prescription | ORAL | AA | Aug 19, 2024 |
Manufacturing Plant Locations New
Granules's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Granules as present at those locations.
| Country | City | Firm Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||
| India |
| |||||||||||
18. HERITAGE PHARMS INC
Heritage Pharmaceuticals Inc has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Heritage Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Jan 3, 2017 |
| 1MG | tablet | Prescription | ORAL | AA | Jan 3, 2017 |
19. HIKMA FARMACEUTICA
Hikma Farmaceutica (portugal) Sa has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Hikma Farmaceutica.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Sep 21, 2011 |
Manufacturing Plant Locations New
Hikma Farmaceutica's manufacturing plants are situated in 1 country - Portugal. Given below are the details of these plant locations as well as the firm names of Hikma Farmaceutica as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Portugal |
| |||
20. HIKMA INTL PHARMS
Hikma International Pharmaceuticals Llc has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Hikma Intl Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Discontinued | ORAL | N/A | Mar 5, 2009 |
| 2MG | tablet | Discontinued | ORAL | N/A | Mar 5, 2009 |
21. HOSPIRA
Hospira Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Jun 15, 1988 |
Manufacturing Plant Locations New
Hospira's manufacturing plants are situated in 3 countries - Australia, United States, Dominican Republic (the). Given below are the details of these plant locations as well as the firm names of Hospira as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Australia |
| |||||||||||||
| United States |
| |||||||||||||
| Dominican Republic (the) |
| |||||||||||||
22. LGM PHARMA
Lgm Pharma Solutions Llc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Lgm Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1.5MG
(reference standard) | tablet | Prescription | ORAL | N/A | Mar 12, 2012 |
Manufacturing Plant Locations New
Lgm Pharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Lgm Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
23. LUPIN LTD
Lupin Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Feb 7, 2023 |
Manufacturing Plant Locations New
Lupin Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Lupin Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
24. MANKIND PHARMA
Mankind Pharma Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Mankind Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Feb 27, 2023 |
Manufacturing Plant Locations New
Mankind Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Mankind Pharma as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| India |
| |||||
25. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Meitheal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Jul 6, 2021 |
26. NATCO
Natco Pharma Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Natco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Jun 20, 2016 |
| 1MG | tablet | Prescription | ORAL | AA | Jun 20, 2016 |
Manufacturing Plant Locations New
Natco's manufacturing plants are situated in 2 countries - United Kingdom, India. Given below are the details of these plant locations as well as the firm names of Natco as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom |
| |||||||||||||
| India |
| |||||||||||||
27. OMNIVIUM PHARMS
Omnivium Pharmaceuticals Llc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Omnivium Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Nov 29, 2022 |
28. OXFORD PHARMS
Oxford Pharmaceuticals Llc has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Oxford Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Prescription | ORAL | AA | Oct 19, 2011 |
| 2MG | tablet | Prescription | ORAL | AA | Oct 19, 2011 |
29. PIRAMAL CRITICAL
Piramal Critical Care Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Piramal Critical.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 25, 2018 |
Manufacturing Plant Locations New
Piramal Critical's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Piramal Critical as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
30. PRINSTON INC
Prinston Pharmaceutical Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Prinston Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 31, 2018 |
31. QUAGEN
Quagen Pharmaceuticals Llc has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Quagen.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Jul 10, 2024 |
| 1MG | tablet | Prescription | ORAL | AA | Jul 10, 2024 |
Manufacturing Plant Locations New
Quagen's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Quagen as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
32. RISING
Rising Pharma Holdings Inc has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Rising.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Dec 29, 2008 |
| 1MG | tablet | Prescription | ORAL | AA | Dec 29, 2008 |
Manufacturing Plant Locations New
Rising's manufacturing plants are situated in 3 countries - United States, Mexico, India. Given below are the details of these plant locations as well as the firm names of Rising as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||||
| Mexico |
| |||||||||||||||||||
| India |
| |||||||||||||||||||
33. SAGENT
Sagent Pharmaceuticals has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Sagent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Feb 21, 2020 |
Manufacturing Plant Locations New
Sagent's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Sagent as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
34. SANDOZ
Sandoz Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | May 14, 2019 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
35. SAPTALIS PHARMS
Saptalis Pharmaceuticals Llc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Saptalis Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/5ML | solution | Prescription | ORAL | AA | Oct 7, 2024 |
36. SOMERSET THERAPS LLC
Somerset Therapeutics Llc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Somerset Theraps Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Jun 23, 2017 |
37. SUN PHARM INDS LTD
Sun Pharmaceutical Industries Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Prescription | ORAL | AA | Aug 18, 2009 |
| 2MG | tablet | Prescription | ORAL | AA | Aug 18, 2009 |
38. SUVEN PHARMS
Suven Pharmaceuticals Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Suven Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/5ML | solution | Prescription | ORAL | AA | Jul 5, 2022 |
39. TEVA PARENTERAL
Teva Parenteral Medicines Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Teva Parenteral.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Sep 10, 1991 |
Manufacturing Plant Locations New
Teva Parenteral's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Teva Parenteral as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
40. UMEDICA
Umedica Laboratories Private Ltd has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Umedica.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Oct 13, 2021 |
Manufacturing Plant Locations New
Umedica's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Umedica as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
41. VELZEN PHARMA PVT
Velzen Pharma Pvt Ltd has filed for 2 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Velzen Pharma Pvt.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | tablet | Prescription | ORAL | AA | Sep 21, 2012 |
| 1MG | tablet | Prescription | ORAL | AA | Sep 21, 2012 |
42. WATSON LABS
Watson Laboratories Inc has filed for 3 different strengths of generic version for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Watson Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | tablet | Discontinued | ORAL | N/A | Approved Prior to Jan 1, 1982 |
| 2MG | tablet | Discontinued | ORAL | N/A | Approved Prior to Jan 1, 1982 |
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Jun 24, 1983 |
43. XIROMED
Xiromed Pharma Espana Sl has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Xiromed.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Prescription | INJECTION | AP | Mar 4, 2021 |
Manufacturing Plant Locations New
Xiromed's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Xiromed as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
44. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 1 generic for Glycopyrrolate. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.2MG/ML | injectable | Discontinued | INJECTION | N/A | Nov 9, 2021 |